|
|
Article: Spectrum Pharmaceuticals said patent litigation relating to sumatriptan injection--the generic version of GlaxoSmithKline's Imitrex Injection--has been dismissed by the US District Court for the District of Delaware pursuant to the previously announced settlement agreement between Spectrum and GSK.(COMPANY NEWS)
- Article from:
- Medical Marketing & Media
- Article date:
- February 1, 2007
CopyrightCOPYRIGHT 2007 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Spectrum Pharmaceuticals said patent litigation relating to sumatriptan injection--the generic version of GlaxoSmithKline's Imitrex Injection--has been dismissed by the US District Court for the District of Delaware pursuant to the previously announced settlement agreement between Spectrum and GSK. In November, Spectrum and GSK reached an agreement to settle patent litigation relating to sumatriptan injection. The terms of the ...
Related newspaper, magazine, and journal articles:
|